Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 11/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.56 |
| ▸ | CPT2 | P23786 | 8/20 | 0.56 |
| ▸ | CPT1B | Q92523 | 4/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.52 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516295 | 1.00 | CPT1A (0.61) | CPT1ATRPV1HSD11B1CPT2CPT1B | |
| SCHEMBL2307678 | 0.97 | CPT1A (0.66) | CPT1ATRPV1HSD11B1CPT2CPT1B | |
| SCHEMBL2307670 | 0.97 | CPT1A (0.66) | CPT1ATRPV1HSD11B1CPT2CPT1B | |
| SCHEMBL13779738 | 0.92 | CPT1A (0.52) | CPT1ATRPV1HSD11B1CPT2CPT1B | |
| SCHEMBL13209702 | 0.92 | CPT1A (0.52) | CPT1ATRPV1HSD11B1CPT2CPT1B | |
| SCHEMBL2637262 | 0.91 | HSD11B1 (0.67) | CPT1ATRPV1HSD11B1CPT2CPT1B | |
| SCHEMBL2637264 | 0.91 | HSD11B1 (0.67) | CPT1ATRPV1HSD11B1CPT2CPT1B | |
| SCHEMBL1953343 | 0.89 | HSD11B1 (0.55) | CPT1ATRPV1HSD11B1CPT2CPT1B | |
| SCHEMBL1953345 | 0.89 | HSD11B1 (0.55) | CPT1ATRPV1HSD11B1CPT2CPT1B | |
| SCHEMBL2308799 | 0.88 | HSD11B1 (0.63) | CPT1ATRPV1HSD11B1CPT2CPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111423432-B | (S) -4/5-phenyl-2- (pyrrolidine-2-yl) thiazole TRPV1 antagonist and preparation and application thereof | 河南大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-111423432-A | (S) -4/5-phenyl-2- (pyrrolidine-2-yl) thiazole TRPV1 antagonist and preparation and application thereof | 河南大学 | 2020-07-17 | — | — | CN | disclosed |
| US-20090318445-A1 | PDF INHIBITORS | NORVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-1973898-A1 | PDF INHIBITORS | Novartis AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007077186-A1 | PDF INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318445-A1 | PDF INHIBITORS | PDF, TIMP3, MMP2 | CPT1A 2339/4885TRPV1 4194/4885HSD11B1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.